Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection

Influence of the vitreomacular interface on the progression of diabetic macular edema after treatment with intravitreal injection of vascular endothelial growth factor inhibitors

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Macular Edema Anti-VEGF Treatment Vitreomacular Interface

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

diabetic macular edema treatable with antiangiogenic drugs

Exclusion criteria

age under 18
cardiovascular events during the last year
previous vitrectomy
previous macular edema treatment during the last 4 months

Treatment and study plan

Intravitreal Ranibizumab injection

Drug

Primary outcomes

Change in best-corrected visual acuity

Time frame: One year

Secondary outcomes

Change in central macular thickness

Time frame: One year
Number of ranibizumab injections

Time frame: One year

Sponsors and collaborators

Lead sponsor

Fundació Institut Germans Trias i Pujol

Other

Registry information

Important dates

Study start: 2014
Primary completion: 2015
Study completion: 2016
First posted: Oct 14, 2016
Registry last updated: Oct 18, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed